Accounting Crisis Deepens for Pharmaceutical Packaging Firm Gerresheimer

The German pharmaceutical packaging specialist Gerresheimer finds itself in a severe predicament, facing a perfect storm of delayed financial reporting, an expanded regulatory probe, and the imminent threat of removal from a key stock index. The company confirmed yesterday that its audited financial statements for 2025 will not be released until June, missing the Deutsche Börse’s regulatory deadline of March 31. This delay could trigger its expulsion from the SDAX.

Shareholder Value Evaporates Amid Uncertainty

The market reaction has been brutal. On Wednesday, the stock plummeted by as much as 18 percent intraday, briefly touching €16.30—a price level not seen since 2009. This represents a catastrophic decline from its mid-2023 peak of approximately €120 per share. Over the past twelve months, shareholder value has been erased by roughly 77 percent, with the company’s market capitalization collapsing from around €4 billion to approximately €650 million today. Following its earlier demotion from the MDAX, the potential loss of its SDAX listing could force further selling by index-bound institutional investors.

Regulatory Scrutiny Focuses on Revenue Recognition

At the heart of the turmoil is an ongoing investigation by the German financial regulator, BaFin. Initiated in September 2025 and subsequently widened, the probe is examining accounting practices from 2024 and 2025. A primary area of focus is the use of “bill-and-hold” bookings, where revenue is recognized before goods have physically left the warehouse. The BaFin has also flagged problematic depreciation calculations at a Swiss subsidiary, alongside discrepancies concerning €65.5 million in leasing liabilities and €29.4 million in development costs.

A second external auditing firm has now been brought in to investigate these irregularities. With the outcome of this review pending, analysts describe the company as a “black box,” making any fundamental valuation currently impossible.

Should investors sell immediately? Or is it worth buying Gerresheimer?

Financial Calendar in Disarray, Covenant Risks Loom

The postponement of the annual report has sent the company’s financial calendar into disarray. First-quarter 2026 results, originally scheduled for April 16, have also been delayed. The Annual General Meeting, set for June 3, has been postponed indefinitely.

A particularly pressing concern involves the company’s substantial debt. With net financial debt of approximately €2.2 billion (as of August 2025), the late filing of the audited statements risks breaching contractual deadlines with lenders. Gerresheimer has already entered into discussions with its creditors to preempt potential covenant violations and secure its financing until the certified report is published in June.

Path Forward Hinges on Two Critical Factors

The immediate future for Gerresheimer depends on two parallel processes. The first is the successful renegotiation with its banking partners to maintain financial stability. The second, and perhaps more decisive, is the final outcome of the BaFin’s examination. Should the audited statements be delivered in June without revealing further accounting errors, the situation could begin to stabilize. Until then, the company remains mired in uncertainty, with investors awaiting clarity from both the boardroom and the regulator.